KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
12.59
+0.34 (2.73%)
At close: Aug 13, 2025, 4:00 PM
12.59
0.00 (0.00%)
Pre-market: Aug 14, 2025, 8:36 AM EDT
KalVista Pharmaceuticals Employees
KalVista Pharmaceuticals had 270 employees as of April 30, 2025. The number of employees increased by 120 or 80.00% compared to the previous year.
Employees
270
Change (1Y)
120
Growth (1Y)
80.00%
Revenue / Employee
n/a
Profits / Employee
-$679,422
Market Cap
626.26M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KALV News
- 2 days ago - Metagenomi Appoints Laurence Reid, PhD to its Board of Directors - GlobeNewsWire
- 3 days ago - KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union - Business Wire
- 10 days ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 20 days ago - KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
- 5 weeks ago - KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results - Business Wire
- 5 weeks ago - KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning - Seeking Alpha
- 5 weeks ago - US FDA approves KalVista Pharma's swelling disorder drug - Reuters